Review
Dermatology
T. Gambichler, S. Boms, L. Susok, H. Dickel, C. Finis, N. Abu Rached, M. Barras, M. Stuecker, D. Kasakovski
Summary: Skin reactions following COVID-19 vaccination can vary from mild injection-site discomfort to severe allergic reactions and autoimmune-mediated conditions. These immune responses may be attributed to molecular mimicry between SARS-CoV-2 components and human proteins.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Virology
Yasmine Slimani, Reda Abbassi, Fatima-Zohra El Fatoiki, Lahoucine Barrou, Soumiya Chiheb
Summary: Emerging reports suggest that COVID-19 may lead to autoimmune and autoinflammatory diseases. This case report describes a patient who developed SLE and antiphospholipid antibody syndrome after contracting COVID-19, leading to skin manifestations and ultimately resulting in death. The pathophysiological mechanisms behind these overlapping disorders in the patient remain unknown, highlighting the growing mystery of the virus and its connection to cutaneous, autoimmune, and autoinflammatory manifestations.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Review
Immunology
Paul Curtiss, Amanda M. Walker, Benjamin F. Chong
Summary: This study reviewed patient cohorts and populations to investigate the progression of cutaneous lupus to systemic lupus. The study found variations in the progression rates between adult and pediatric groups, which were attributed to differences in patient populations, study design, diagnostic criteria, and follow-up time. Risk factors associated with the development of systemic lupus included positive anti-nuclear antibodies, hematologic abnormalities, and a higher number of lupus classification criteria at baseline.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Ilaria Mormile, Francesca Della Casa, Angelica Petraroli, Alessandro Furno, Francescopaolo Granata, Giuseppe Portella, Francesca Wanda Rossi, Amato de Paulis
Summary: This study evaluated the efficacy and safety of mRNA COVID-19 vaccines in patients with systemic lupus erythematosus (SLE). The results showed that the vaccines produced a satisfactory antibody response in SLE patients without influencing disease activity.
Article
Oncology
Astha Thakkar, Jesus D. Gonzalez-Lugo, Niyati Goradia, Radhika Gali, Lauren C. Shapiro, Kith Pradhan, Shafia Rahman, So Yeon Kim, Brian Ko, R. Alejandro Sica, Noah Kornblum, Lizamarie Bachier-Rodriguez, Margaret McCort, Sanjay Goel, Roman Perez-Soler, Stuart Packer, Joseph Sparano, Benjamin Gartrell, Della Makower, Yitz D. Goldstein, Lucia Wolgast, Amit Verma, Balazs Halmos
Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.
Article
Medicine, Research & Experimental
Qi Tang, Fen Li, Jing Tian, Jin Kang, Jinshen He
Summary: There are concerns about the safety of SARS-CoV-2 inactivated vaccines among patients with SLE, but vaccination is safe in stable SLE patients.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Peng Wang, Jing Ni, Ya-Ya Chu, Qing-Qing Chen, Cong Chen, Ruo-Di Zhang, Ling-Qiong Jiang, Yan Zhao, Jun He, De-Guang Wang, Gui-Hong Wang, Hai-Feng Pan, Guo-Cui Wu
Summary: This study investigated the seroreactivity of COVID-19 vaccination and its adverse events in SLE patients, RA patients, and healthy controls. The results showed that there were no significant differences in the seroprevalence of IgG and IgM antibodies against SARS-CoV-2 and the reported adverse events among the three groups. This suggests that the COVID-19 vaccine is safe and effective for SLE and RA patients.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Rheumatology
Shaun Ye Song Tan, Aaron Mingyang Yee, Jackie Jia Lin Sim, Cynthia Ciwei Lim
Summary: This study aimed to assess the effectiveness, efficacy, acceptance, and safety of COVID-19 vaccination in SLE patients. The study found that post-vaccine COVID-19 infections, severe flares, and adverse events were infrequent in SLE patients, while seropositivity and acceptance were high.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Koya Nakatani, Etsuro Sakata, Masakazu Fujihara, Kaoru Mizukawa, Takashi Koyama
Summary: This case report describes an 80-year-old male patient who developed vasculitis symptoms after receiving a COVID-19 vaccine, including persistent high fever, lower limb pain, and difficulty walking. FDG PET/CT showed abnormal metabolism along the vessels in multiple areas of the body, and temporal artery biopsy confirmed the presence of arteritis.
CLINICAL NUCLEAR MEDICINE
(2022)
Article
Cell Biology
Jasmin Knopf, Johanna Sjowall, Martina Frodlund, Jorma Hinkula, Martin Herrmann, Christopher Sjowall
Summary: The severity of COVID-19 is related to immune response, which raises concerns for patients with autoimmune disorders. Thromboembolism, characterized by the occlusion of vessels by NETs, is a complication of COVID-19. This study suggests that an imbalance in NET formation and clearance may exacerbate autoimmunity and disease severity. Serologic evidence of SARS-CoV-2 exposure has minor impact on the course of SLE.
Review
Rheumatology
Resit Yildirim, Tatiana Oliveira, David Alan Isenberg
Summary: In recent years, there have been efforts to improve the prognosis and outcome in patients with autoimmune inflammatory rheumatic diseases by using treat-to-target strategy and early intervention strategies with immunosuppressive agents. However, infectious complications due to medication side effects remain a major concern. Vaccination programmes and vaccine immunity play a crucial role in patients with SLE in terms of morbidity and mortality. Although research on vaccines' efficacy and immune response in immunosuppressed patients has increased, there is still a lack of data investigating these parameters for those receiving biological agents, leading to a lack of consensus on a vaccination policy for patients with SLE.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Immunology
Nefeli Giannopoulou, Latika Gupta, Laura Andreoli, Daniele Lini, Elena Nikiphorou, Rohit Aggarwal, Vikas Agarwal, Ioannis Parodis
Summary: The study found that COVID-19 vaccination in pregnant SLE patients was safe and did not exacerbate their autoimmune disease. Minor vaccine-related adverse events were reported but did not affect daily functioning and resolved within a few days. No adverse pregnancy outcomes were reported. Overall, the risk/benefit ratio of COVID-19 vaccination in SLE patients and high-risk pregnancies is favorable.
AUTOIMMUNITY REVIEWS
(2023)
Article
Immunology
Yuval Ishay, Ariel Kenig, Tehila Tsemach-Toren, Radgonde Amer, Limor Rubin, Yoav Hershkovitz, Fadi Kharouf
Summary: Vaccines are seen as a potential solution to the COVID-19 pandemic, but widespread distribution has been hindered by concerns over side effects. In Israel, where a large percentage of the population has been vaccinated, cases of autoimmune conditions following vaccination have been observed, but they generally have mild symptoms requiring modest treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Health Care Sciences & Services
Marc Scherlinger, Naimah Zein, Jacques-Eric Gottenberg, Marianne Riviere, Jean-Francois Kleinmann, Jean Sibilia, Laurent Arnaud
Summary: This study evaluated the difficulties faced by systemic lupus erythematosus (SLE) patients during the early COVID-19 pandemic and their impact on mental health. The findings showed that many patients experienced challenges in accessing healthcare and treatment, and had high levels of psychological distress.
Article
Immunology
Anna Sabrina Kuechler, Sandra Weinhold, Fritz Boege, Ortwin Adams, Lisa Mueller, Florian Babor, Sabrina B. Bennstein, T-X Uyen Pham, Maryam Hejazi, Sarah B. Reusing, Derik Hermsen, Markus Uhrberg, Karin Schulze-Bosse
Summary: This study describes a diagnostic procedure for scheduling (re-)vaccination against SARS-CoV-2 based on individual humoral immunization status. The researchers monitored individuals before, during, and six months after vaccination with the Spikevax vaccine. The study found that measuring serum-based SARS-CoV-2 antibody levels could potentially support personalized vaccination schedules.
